The researchers investigated whether there are associations between different classes of glucose-lowering drugs and risk of COVID-19-related mortality in people with type 2 diabetes.
In this featured study from the New England Journal of Medicine, British researchers share the results of a phase 2 trial for semaglutide in 230 patients with NASH.
SGLT-2 inhibitors are considered the drugs of choice for patients with very high or high cardiovascular risk with or without kidney disease.
Imeglimin is the first in class tetrahydrotriazine‐containing oral glucose-lowering agent
Imeglimin is first in a new class of oral antidiabetic agents. In this featured phase 3 trial from France, researchers describe outcomes 107 patients with type 2 diabetes.
Hypothalamic obesity can be an acquired condition, either through a malfunctioning hypothalamus or as a result of treatment for a brain tumor.
Proton pump inhibitors are FDA-approved for gastroesophageal reflux disease, gastric ulcers and other conditions, but not type 2 diabetes.
This study was launched to analyze the effect of setmelanotide, a melanocortin 4 receptor agonist, on weight loss and hunger reduction in patients with obesity and a confirmed diagnosis of Bardet-Biedl syndrome (BBS) or Alströmsyndrome (AS).
At the Endocrine Society’s annual meeting, ENDO 2021, Seema Kumar from the Mayo Clinic presented a review covering the evaluation and assessment of pediatric obesity and type 2 diabetes mellitus.
Overweight or obese men frequently have low serum testosterone concentrations, which is associated with increased risk of type 2 diabetes.
Certain risk factors were consistent predictors of DFU hospitalization regardless of FDS phase, making a case for a temporal shift of inpatient care strategies over those decades.
